Exploration of Clinical Characteristics and Drug Treatment of Inflammatory Bowel Disease Complicated with Autoimmune Diseases
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v4i3.1260
Abstract
Objective: To analyze the clinical characteristics and drug treatment outcomes of inflammatory bowel disease (IBD) complicated with autoimmune diseases. Methods: A total of 200 patients with IBD and autoimmune diseases were selected as the observation group from January 2022 to June 2023. In addition, 200 patients with simple IBD during the same period were selected as the control group. The general and clinical data of the two groups of patients were collected and analyzed to compare their clinical characteristics and drug treatment outcomes. Results: ① There were no significant differences in gender, age, lesion location, and clinical type between the two groups (P > 0.05). However, the two groups differed significantly in terms of disease duration, severity of the condition, and extraintestinal symptoms (P < 0.05). ② There was no significant difference in the use of microbial preparations between the two groups (P > 0.05). The observation group had a higher usage rate of steroids compared to the control group, while the usage rate of aminosalicylate suppositories was lower in the observation group than in the control group (P < 0.05). ③ There was no significant difference in treatment efficacy between the two groups (P > 0.05). Conclusion: Patients with IBD complicated by autoimmune diseases have longer disease duration, more severe conditions, and more extraintestinal symptoms compared to those with simple IBD. The usage rate of steroids is higher, while the usage rate of aminosalicylate suppositories is lower in the treatment plan for the former group. Nevertheless, the overall effectiveness is comparable to that of patients with simple IBD, and the overall prognosis is relatively favorable.
Keywords
inflammatory bowel disease, autoimmune diseases, clinical characteristics, drug treatment outcomes
Full Text
PDF - Viewed/Downloaded: 7 TimesReferences
[1] Zhang ZY, Huang L, Huang JQ, et al. Immune regulation: A new perspective on the treatment of inflammatory bowel disease from the perspective of lung. Chinese Journal of Clinical Medicine, 2023, 15(13): 112-116.
[2] Wu Y, Chen L, Ni PP, et al. Study on the predictive value of systemic immune inflammation index and prognostic nutritional index for muscle loss in patients with inflammatory bowel disease. China Medical Journal, 2023, 58(5): 494-498.
[3] Shen J. Impact of immunosuppressive and biological therapies on vaccination in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology, 2022, 31(4): 372-375.
[4] Hao YP, Han J, Teng SZ, et al. Effects of combination therapy of biologics and immunosuppressants on nutritional status and inflammatory response in patients with inflammatory bowel disease. Chinese Journal of Medical Research, 2022, 20(18): 43-46.
[5] Zu XM, Xu S, Lin LH, et al. Diagnosis and treatment strategies for inflammatory bowel disease concomitant with rheumatic immune diseases. Chinese Journal of Inflammatory Bowel Disease, 2021, 5(1): 21-26.
[6] Liu WD, Feng F. Effects of enteral immune microecological nutritional support on serum inflammatory factors and intestinal mucosal Th17A expression in rats with inflammatory bowel disease. Journal of Shanxi Medical University, 2021, 52(8): 1029-1033.
[7] Li BY, Bu XD, Chen WX, et al. Current research status of pathogenesis and treatment of inflammatory bowel disease: miRNAs and intestinal immunity and barrier function. Gastroenterology, 2020, 25(11): 687-691.
[8] Yang H, Zhang MG, Wang ZD, et al. Correlation study of serum immune-inflammatory related protein complexes, 25-hydroxyvitamin D, adipocytokines with disease activity and intestinal flora of patients with inflammatory bowel disease. Modern Advances in Biomedicine, 2022, 22(14): 2653-2657.
[2] Wu Y, Chen L, Ni PP, et al. Study on the predictive value of systemic immune inflammation index and prognostic nutritional index for muscle loss in patients with inflammatory bowel disease. China Medical Journal, 2023, 58(5): 494-498.
[3] Shen J. Impact of immunosuppressive and biological therapies on vaccination in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology, 2022, 31(4): 372-375.
[4] Hao YP, Han J, Teng SZ, et al. Effects of combination therapy of biologics and immunosuppressants on nutritional status and inflammatory response in patients with inflammatory bowel disease. Chinese Journal of Medical Research, 2022, 20(18): 43-46.
[5] Zu XM, Xu S, Lin LH, et al. Diagnosis and treatment strategies for inflammatory bowel disease concomitant with rheumatic immune diseases. Chinese Journal of Inflammatory Bowel Disease, 2021, 5(1): 21-26.
[6] Liu WD, Feng F. Effects of enteral immune microecological nutritional support on serum inflammatory factors and intestinal mucosal Th17A expression in rats with inflammatory bowel disease. Journal of Shanxi Medical University, 2021, 52(8): 1029-1033.
[7] Li BY, Bu XD, Chen WX, et al. Current research status of pathogenesis and treatment of inflammatory bowel disease: miRNAs and intestinal immunity and barrier function. Gastroenterology, 2020, 25(11): 687-691.
[8] Yang H, Zhang MG, Wang ZD, et al. Correlation study of serum immune-inflammatory related protein complexes, 25-hydroxyvitamin D, adipocytokines with disease activity and intestinal flora of patients with inflammatory bowel disease. Modern Advances in Biomedicine, 2022, 22(14): 2653-2657.
Copyright © 2023 Jiawei Guo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License